User:Betsy Johns/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 33: Line 33:
== Disease ==
== Disease ==
-
Obesity and nonalcoholic fatty liver disease result from an accumulation of triglycerides within the body. Recently, DGAT has become a therapeutic target for obesity and nonalcoholic fatty liver disease in order to reduce triglyceride storage within the body. Different inhibitors have been created, such as AstraZeneca’s direct inhibitor AZD7687 [https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.12221]. However, while the triglyceride accumulation decreased, side effects did occur, such as diarrhea and other adverse GI symptoms. Additionally, congenital protein-losing enteropathy (PLE) is a GI disorder that results in the malabsorption of fat and a deficiency in fat-soluble vitamins. There has been a case study of congenital PLE patients [https://www.nature.com/articles/ejhg20165] that have a homozygous missense Leu295Pro mutation in their DGAT enzymes. This mutation is in a helix of the MBOAT core. Proline is a helix breaker, so it is hypothesized that this mutation breaks a helix in the MBOAT core that impacts its enzymatic activity and ability to make triacylglycerides. Without proper DGAT function to produce triacylglycerides, there is a decrease in albumin, which is a protein that helps prevent fluid leaking out of the liver and blood vessels. This decrease in albumin then leads to decreased efficiency in nutrient transport.
+
Obesity and nonalcoholic fatty liver disease result from an accumulation of triglycerides within the body. Recently, DGAT has become a therapeutic target for obesity and nonalcoholic fatty liver disease in order to reduce triglyceride storage within the body. Different inhibitors have been created, such as AstraZeneca’s direct inhibitor AZD7687 <ref name="Denison">PMID: 24118885</ref>. However, while the triglyceride accumulation decreased, side effects did occur, such as diarrhea and other adverse GI symptoms. Additionally, congenital protein-losing enteropathy (PLE) is a GI disorder that results in the malabsorption of fat and a deficiency in fat-soluble vitamins. There has been a case study of congenital PLE patients that have a homozygous missense Leu295Pro mutation in their DGAT enzymes <ref name="Stephen">PMID: 26883093</ref>. This mutation is in a helix of the MBOAT core. Proline is a helix breaker, so it is hypothesized that this mutation breaks a helix in the MBOAT core that impacts its enzymatic activity and ability to make triacylglycerides. Without proper DGAT function to produce triacylglycerides, there is a decrease in albumin, which is a protein that helps prevent fluid leaking out of the liver and blood vessels. This decrease in albumin then leads to decreased efficiency in nutrient transport.

Revision as of 19:03, 5 April 2021

Diacylglycerol acyltransferase, DGAT

DGAT 6vz1

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 Wang L, Qian H, Nian Y, Han Y, Ren Z, Zhang H, Hu L, Prasad BVV, Laganowsky A, Yan N, Zhou M. Structure and mechanism of human diacylglycerol O-acyltransferase 1. Nature. 2020 May;581(7808):329-332. doi: 10.1038/s41586-020-2280-2. Epub 2020 May, 13. PMID:32433610 doi:http://dx.doi.org/10.1038/s41586-020-2280-2
  2. 2.0 2.1 Sui X, Wang K, Gluchowski NL, Elliott SD, Liao M, Walther TC, Farese RV Jr. Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme. Nature. 2020 May;581(7808):323-328. doi: 10.1038/s41586-020-2289-6. Epub 2020 May, 13. PMID:32433611 doi:http://dx.doi.org/10.1038/s41586-020-2289-6
  3. 3.0 3.1 Denison H, Nilsson C, Lofgren L, Himmelmann A, Martensson G, Knutsson M, Al-Shurbaji A, Tornqvist H, Eriksson JW. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2014 Apr;16(4):334-43. doi: 10.1111/dom.12221. Epub 2013 Oct, 31. PMID:24118885 doi:http://dx.doi.org/10.1111/dom.12221
  4. 4.0 4.1 Stephen J, Vilboux T, Haberman Y, Pri-Chen H, Pode-Shakked B, Mazaheri S, Marek-Yagel D, Barel O, Di Segni A, Eyal E, Hout-Siloni G, Lahad A, Shalem T, Rechavi G, Malicdan MC, Weiss B, Gahl WA, Anikster Y. Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. Eur J Hum Genet. 2016 Aug;24(9):1268-73. doi: 10.1038/ejhg.2016.5. Epub 2016 Feb , 17. PMID:26883093 doi:http://dx.doi.org/10.1038/ejhg.2016.5
  5. Rebello CJ, Greenway FL. Obesity medications in development. Expert Opin Investig Drugs. 2020 Jan;29(1):63-71. doi:, 10.1080/13543784.2020.1705277. Epub 2019 Dec 19. PMID:31847611 doi:http://dx.doi.org/10.1080/13543784.2020.1705277
  6. Scott SA, Mathews TP, Ivanova PT, Lindsley CW, Brown HA. Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta. 2014 Aug;1841(8):1060-84. doi:, 10.1016/j.bbalip.2014.01.009. Epub 2014 Jan 15. PMID:24440821 doi:http://dx.doi.org/10.1016/j.bbalip.2014.01.009

Student Contributors

  • Betsy Johns
  • Elise Wang
  • Tyler Bihasa

Proteopedia Page Contributors and Editors (what is this?)

Betsy Johns

Personal tools